
HEK293/RARβ Luciferase Reporter Cell Line
Item | Cat# | Price |
Stable Cell Line | SNB-NR-0002 | $19,800 |
Compound Testing Services | CT-001 | $1,850 per 384w plate (Up To 16 cpds Dose) |
Product Description
RARβ (Retinoic Acid Receptor beta) is another subtype of the retinoic acid receptor (RAR) family within the nuclear receptor superfamily, alongside RARα and RARγ. It also acts as a ligand-activated transcription factor that binds retinoic acid to regulate target gene expression. RARβ exhibits tissue-specific distribution, with predominant expression in the central nervous system (especially the striatum, hippocampus, and olfactory bulb), inner ear, skin, lung, and certain mesenchymal tissues. Its core functions include regulating cell growth, differentiation, and apoptosis; participating in nervous system formation, inner ear development (auditory function), and limb patterning during embryogenesis; and inhibiting excessive cell proliferation in adults, acting as a tumor suppressor — downregulation of RARβ expression is closely associated with the development and progression of various cancers (e.g., lung, breast, and head & neck cancers).
Screeningbio’s HEK293/RARβ Luciferase Reporter cell line contains human RARβ gene and a luciferase gene under the control of retinoic acid response elements. The cell line is designed to detect the response to the stimulation of RARβ ligands. Promega One-Glo kit can be used to detect the signal.
Product Specifications
Target Type | Nuclear Receptor |
Species | Human |
HGNC Symbol | RARB |
Accession Number | NM_000965 (Hs) |
Parental Line | HEK293 |
Lot# | See Vial |
Storage | Liquid Nitrogen |
Data
![HEK293/RARβ Luciferase Reporter Agonist Assay. HEK293/RARβ Luciferase Reporter cells were treated with agonist. The assay was run based on Promega ONE-GLOTM Luciferase Assay System. Non-linear regression was used to plot activity changes vs. [Compound, M], and EC50 values were determined, using GraphPad Prism software.](https://static.wixstatic.com/media/cbf7de_1d62f43611134f7fbc9d941605560336~mv2.png/v1/fill/w_67,h_67,al_c,q_85,usm_0.66_1.00_0.01,blur_2,enc_auto/cbf7de_1d62f43611134f7fbc9d941605560336~mv2.png)
Target Background
RARβ (Retinoic Acid Receptor beta) is another subtype of the retinoic acid receptor (RAR) family within the nuclear receptor superfamily, alongside RARα and RARγ. It also acts as a ligand-activated transcription factor that binds retinoic acid to regulate target gene expression. RARβ exhibits tissue-specific distribution, with predominant expression in the central nervous system (especially the striatum, hippocampus, and olfactory bulb), inner ear, skin, lung, and certain mesenchymal tissues. Its core functions include regulating cell growth, differentiation, and apoptosis; participating in nervous system formation, inner ear development (auditory function), and limb patterning during embryogenesis; and inhibiting excessive cell proliferation in adults, acting as a tumor suppressor — downregulation of RARβ expression is closely associated with the development and progression of various cancers (e.g., lung, breast, and head & neck cancers).
Screeningbio’s HEK293/RARβ Luciferase Reporter cell line contains human RARβ gene and a luciferase gene under the control of retinoic acid response elements. The cell line is designed to detect the response to the stimulation of RARβ ligands. Promega One-Glo kit can be used to detect the signal.
